全文获取类型
收费全文 | 1177篇 |
免费 | 78篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 33篇 |
妇产科学 | 26篇 |
基础医学 | 144篇 |
口腔科学 | 26篇 |
临床医学 | 125篇 |
内科学 | 298篇 |
皮肤病学 | 5篇 |
神经病学 | 154篇 |
特种医学 | 53篇 |
外科学 | 91篇 |
综合类 | 6篇 |
预防医学 | 81篇 |
眼科学 | 12篇 |
药学 | 117篇 |
中国医学 | 3篇 |
肿瘤学 | 84篇 |
出版年
2022年 | 15篇 |
2021年 | 32篇 |
2020年 | 11篇 |
2019年 | 19篇 |
2018年 | 27篇 |
2017年 | 16篇 |
2016年 | 32篇 |
2015年 | 20篇 |
2014年 | 35篇 |
2013年 | 38篇 |
2012年 | 57篇 |
2011年 | 68篇 |
2010年 | 35篇 |
2009年 | 31篇 |
2008年 | 49篇 |
2007年 | 49篇 |
2006年 | 43篇 |
2005年 | 51篇 |
2004年 | 49篇 |
2003年 | 43篇 |
2002年 | 61篇 |
2001年 | 32篇 |
2000年 | 38篇 |
1999年 | 26篇 |
1998年 | 19篇 |
1996年 | 14篇 |
1995年 | 5篇 |
1994年 | 8篇 |
1993年 | 6篇 |
1992年 | 19篇 |
1991年 | 24篇 |
1990年 | 19篇 |
1989年 | 29篇 |
1988年 | 26篇 |
1987年 | 35篇 |
1986年 | 22篇 |
1985年 | 18篇 |
1984年 | 14篇 |
1983年 | 9篇 |
1982年 | 15篇 |
1981年 | 7篇 |
1979年 | 12篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1972年 | 9篇 |
1971年 | 8篇 |
1970年 | 4篇 |
1968年 | 5篇 |
1967年 | 6篇 |
1965年 | 5篇 |
排序方式: 共有1259条查询结果,搜索用时 15 毫秒
101.
102.
Anaplastic thyroid carcinoma (ATC) is the rarest, but deadliest histologic type among thyroid malignancies, with a dismal median survival of 3-9 mo. Even though ATC accounts for less than 2% of all thyroid tumors, it is responsible for 14%-39% of thyroid carcinoma-related deaths. ATC clinically presents as a rapidly growing mass in the neck, associated with dyspnoea, dysphagia and vocal cord paralysis. It is usually locally advanced and often metastatic at initial presentation. For operable diseases, the combination of radical surgery with adjuvant radiotherapy or chemotherapy, using agents such as doxorubicin and cisplatin, is the best treatment strategy. Cytotoxic drugs for advanced/metastatic ATC are poorly effective. On the other hand, targeted agents might represent a viable therapeutic option. Axitinib, combretastatin A4, sorafenib and imatinib have been tested in small clinical trials of ATC, with a promising disease control rate ranging from 33% to 75%. Other clinical trials of targeted therapy for thyroid carcinoma are currently ongoing. Biological agents that are under investigation include pazopanib, gefitinib and everolimus. With the very limited therapeutic armamentarium available at the present time, targeted therapy constitutes an exciting new horizon for ATC. In future, biological agents will probably represent the standard of care for this aggressive malignancy, in the same fashion as it has recently occurred for other chemo-refractory tumors, such as kidney and hepatic cancer. 相似文献
103.
Rosse Mary Falcón‐Antenucci DDS MSc Eduardo Piza Pellizzer DDS MS PhD Paulo Sergio Perri De Carvalho Marcelo Coelho Goiato DDS MS PhD Pedro Yoshito Noritomi MSc PhD 《Journal of prosthodontics》2010,19(5):381-386
Purpose: The aim of this study was to assess the influence of cusp inclination on stress distribution in implant‐supported prostheses by 3D finite element method. Materials and Methods: Three‐dimensional models were created to simulate a mandibular bone section with an implant (3.75 mm diameter × 10 mm length) and crown by means of a 3D scanner and 3D CAD software. A screw‐retained single crown was simulated using three cusp inclinations (10°, 20°, 30°). The 3D models (model 10d, model 20d, and model 30d) were transferred to the finite element program NeiNastran 9.0 to generate a mesh and perform the stress analysis. An oblique load of 200 N was applied on the internal vestibular face of the metal ceramic crown. Results: The results were visualized by means of von Mises stress maps. Maximum stress concentration was located at the point of application. The implant showed higher stress values in model 30d (160.68 MPa). Cortical bone showed higher stress values in model 10d (28.23 MPa). Conclusion: Stresses on the implant and implant/abutment interface increased with increasing cusp inclination, and stresses on the cortical bone decreased with increasing cusp inclination. 相似文献
104.
105.
Once abandoned because of devastating teratogenic effects, thalidomide has reemerged as an alternative treatment in many dermatologic diseases. In 1998, thalidomide became FDA approved for the acute treatment and suppression of the cutaneous manifestations of erythema nodosum leprosum (ENL). ENL is a systemic disorder that typically occurs after several years of antileprosy treatments, usually for lepromatous leprosy. Off-label uses for thalidomide include: aphthous stomatitis, Beh?et disease, pyoderma gangrenosum, chronic discoid lupus erythematosus, systemic lupus erythematosus, lichen planus, prurigo nodularis and sarcoidosis. This review examines the background, pharmacokinetics, mechanism of action, side-effects, and indications of thalidomide. 相似文献
106.
Severe sepsis in transplant recipients results in an extremely high morbidity mortality rate. Microvascular alterations play an important role in the development of sepsis-induced organ dysfunction. Therefore, addition to standard treatment, which we divide into prophylaxis, preemptive therapy, and therapy, activated protein C (or Drotrecogin Alpha Activated [DAA]) represents a radically new approach for these patients. Herein we have reported the first trials evaluating the use of DAA in transplant recipients experiencing sepsis. Comparable trials in humans are still not available for the other coagulation, inhibitor antithrombin. We also report clinical trials discussing whether hyperimmune products reduce the infection rate during myelosuppression, but further trials are requested for the feasible evaluation of these products. 相似文献
107.
108.
Dario Di Perri Emmanuel Jouglar Ellen Blanc Anne Ducassou Aymeri Huchet Cline Vigneron Alexandre Escande Sophie Chapet Julie Leseur Valrie Bernier Christian Carrie Valentine Martin Line Claude 《The British journal of radiology》2021,94(1125)
Objectives:While hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hypofractionated regimens at a young age. In this context, we report the preliminary acute (<3 months from SBRT) and middle-term (3–24 months) toxicity results of a national prospective study investigating SBRT in pediatric patients.Methods:Between 2013 and 2019, 61 patients were included. The first 40 patients (median age: 12 y, range: 3–20) who completed a 2-year-follow-up were included in the present analysis. SBRT was used for treating lung, brain or (para)spinal lesions, either as first irradiation (35%) or in the reirradiation setting (65%).Results:Acute and middle-term grade ≥2 toxicities occurred in 12.5 and 7.5% of the patients, respectively. No grade ≥4 toxicities occurred. Almost all toxicities occurred in the reirradiation setting.Conclusion:SBRT showed a favorable safety profile in young patients treated for lung, brain, and (para)spinal lesions.Advances in knowledge:SBRT appeared to be safe in pediatric patients treated for multiple oncology indications. These results support further evaluation of SBRT, which may have a role to play in this patient population in the future. 相似文献
109.
Giuseppe Nanni Pietro Familiari Alessandro Mor Amerigo Iaconelli Vincenzo Perri Francesco Rubino Giuseppe Boldrini Maria Paola Salerno Laura Leccesi Samuele Iesari Liliana Sollazzi Valter Perilli Marco Castagneto Gertrude Mingrone Guido Costamagna 《Obesity surgery》2012,22(12):1897-1902
Background
The effectiveness of restrictive procedures has been inferior to that of malabsorbitive ones. Recent variants of restrictive procedures, i.e., gastric banding and sleeve gastrectomy, confirm the strive for more efficacious solutions with less complications. We investigated the balance between effectiveness and complications for a new restrictive procedure, a Transoral Endoscopic Vertical Gastroplasty (TOGa?)Methods
Seventy-nine morbidly obese patients were submitted to one out of three surgical procedures: TOGa? (29 patients), laparoscopic gastric bypass (LRYGBP; 20 patients), and biliopancreatic diversion (BPD; 30 patients). Mean BMI were 41.7 (35.4?C46.6), 44.8 (36.4?C54), and 47.5 (41?C60.3), respectively. All the patients reached a 2-year follow-up.Results
In TOGa? group BMI, respectively at 12 and 24?months, was 34.5 and 35.5, with 44 and 48.3?% of patients with BMI lower than 35. In LRYGBP group, BMI was 30.7 and 29.2?kg/m2, with 80 and 85?% of patients with BMI?<?35. In BPD group, BMI was 30 and 29.6?kg/m2, with 100 and 93.3?% of patients with BMI?<?35. In TOGa? group, 59?% of patients with an initial BMI?<?45 reached a BMI?<?35, in comparison to 48?% recorded in the whole group and to 14.3?% in patients with initial BMI????45.Conclusions
In selected patients, TOGa?, was associated with good results after two years in terms of weight loss, even in comparison with LRYGBP and BPD. Minimal trauma, absence of complications, and short hospital stay justify this procedure for patients with low BMI. 相似文献110.
Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females 总被引:5,自引:0,他引:5
S. Bertelloni G. I. Baroncelli M. C. Sorrentino G. Perri G. Saggese 《European journal of pediatrics》1998,157(5):363-367
To evaluate the effect of central precocious puberty (CPP) and its treatment with gonadotropin-releasing hormone (GnRH) analogues
on final height and peak bone mass (PBM), we measured lumbar bone mineral density (BMD) in 23 girls at final height. Patients
were distributed in two groups. Group 1: 14 patients with progressive CPP were treated with GnRH analogues; seven patients
received buserelin (1600 μg/daily), subsequently switched to depot triptorelin (60 μg/kg/26–28 days); seven patients were
treated with depot triptorelin (60 μg/kg/26–28 days); mean age of treatment was 6.2 years (range 2.7–7.8 years); the treatment
was discontinued at the mean age of 10.1 years (range 8.7–11.3 years); final height was reached at the mean age 13.4 years
(range 12.0–14.9 years). Group 2: 9 patients (mean age 6.5 years, range 4.8–7.7 years) with a slowly progressing variant of
CPP were followed without treatment; final height was reached at the mean␣age␣13.6 years (range 12.5–14.8 years). Lumbar BMD
(L2-L4 by dual energy X-ray␣absorptiometry) was measured in all patients at final height. In group 1, final height␣(158.9 ± 5.4 cm)
was significantly greater than the pre-treatment predicted height (153.5 ± 7.2 cm, P < 0.001), but significantly lower than mid-parental height (163.2 ± 6.2 cm, P < 0.005). Subdividing the girls of group 1 according to the bone age at discontinuation of therapy (i.e. ≤11.5 years, n = 5, or ≥12.0 years, n = 9), the former patients had a final height significantly higher than the latter (163.7 ± 3.9 cm vs 156.5 ± 4.6 cm, P < 0.02). In group 2, final height (161.8 ± 4.6 cm) was similar to the pre-treatment predicted height (163.1 ± 6.2 cm, P = NS) and was not significantly different from mid-parental height (161.0 ± 5.9 cm). BMD values (group 1: 1.11 ± 0.14 g/cm2, group 2: 1.22 ± 0.08 g/cm2) were not significantly different from those of a control group (1.18 ± 0.10 g/cm2; n = 20, age 16.3–20.5 years) and the patients' mothers (group 1: 1.16 ± 0.07 g/cm2, n = 11, age 32.9–45.1 years; group 2: 1.20 ± 0.08 g/cm2, n = 7, age 33.5–46.5 years). In group 1, the girls who stopped therapy at a bone age ≤11.5 years had significantly higher BMD
(1.22 ± 0.10 g/cm2) compared to those who discontinued therapy at a bone age ≥12.0 years (1.04 ± 0.12 g/cm2, P < 0.05).
Conclusion In girls with progressive CPP, long-term treatment with GnRH analogues improves final height. A subset of patients with CPP
does not require treatment because good statural outcome (slowly progressing variant). In CPP, the abnormal onset of puberty
and the long-term GnRH analogue treatment do not impair the achievement of PBM. In GnRH treated patients, the discontinuation
of therapy at an appropriate bone age for pubertal onset may improve both final height and PBM.
Received: 5 June 1997 / Accepted in revised form 21 November 1997 相似文献